Imiglucerase biosimilar - ISU Abxis

Drug Profile

Imiglucerase biosimilar - ISU Abxis

Alternative Names: Abcertin; ISU-302

Latest Information Update: 31 Aug 2016

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator ISU Abxis
  • Class Glucosidases
  • Mechanism of Action Glucosylceramidase replacements
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Marketed Gaucher's disease

Most Recent Events

  • 22 Aug 2016 ISU Abxis withdraws a phase III trial for Gaucher's disease prior to enrolment in South Korea (NCT01161914)
  • 27 Oct 2013 Biomarkers information updated
  • 31 Jan 2012 Phase-III clinical trials in Gaucher's disease in Egypt (IV)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top